The conference arrives at a critical juncture: while treatment options for heart failure continue to evolve, fewer than one in four eligible patients with HFrEF currently receive full guideline-directed medical therapy. The event seeks to address this disparity by convening a multidisciplinary care team, including nurses, pharmacists, and physicians, to translate complex science into actionable bedside strategies.
This year’s program marks a record for the organization, featuring more than 50 scientific sessions and 750 ePosters. A central focus is placed on device innovation, highlighted by the dedicated Devices in Heart Failure session on October 9. Attendees will also examine advancements in areas ranging from cardio-oncology and transplantation to the integration of artificial intelligence in clinical workflows.





Comments (0)
No comments yet. Be the first!